Search Result

Results for "

gastrointestinal diseases

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (6) Adrenergic Receptor (1) Amyloid-β (1) Angiotensin-converting Enzyme (ACE) (1) Antibiotic (4) Apical Sodium-Dependent Bile Acid Transporter (1) Apoptosis (1) Bacterial (14) Cholecystokinin Receptor (2) Cholinesterase (ChE) (3) COX (1) Cytochrome P450 (2) Dopamine Receptor (5) Drug Metabolite (3) Endogenous Metabolite (3) FXR (4) G protein-coupled Bile Acid Receptor 1 (3) GSK-3 (1) Histamine Receptor (3) Isotope-Labeled Compounds (2) LRRK2 (1) mAChR (2) Monoamine Oxidase (2) Neurokinin Receptor (1) PDGFR (1) Phosphodiesterase (PDE) (1) Potassium Channel (2) Proton Pump (3) Reactive Oxygen Species (2) RET (1) ROCK (1) Toll-like Receptor (TLR) (1) VEGFR (1)
By Research Areas:	Cancer (12) Cardiovascular Disease (8) Endocrinology (2) Infection (13) Inflammation/Immunology (20) Metabolic Disease (17) Neurological Disease (15)

By Targets:

5-HT Receptor (6)

Adrenergic Receptor (1)

Amyloid-β (1)

Angiotensin-converting Enzyme (ACE) (1)

Antibiotic (4)

Apical Sodium-Dependent Bile Acid Transporter (1)

Apoptosis (1)

Bacterial (14)

Cholecystokinin Receptor (2)

Cholinesterase (ChE) (3)

COX (1)

Cytochrome P450 (2)

Dopamine Receptor (5)

Drug Metabolite (3)

Endogenous Metabolite (3)

FXR (4)

G protein-coupled Bile Acid Receptor 1 (3)

GSK-3 (1)

Histamine Receptor (3)

Isotope-Labeled Compounds (2)

LRRK2 (1)

mAChR (2)

Monoamine Oxidase (2)

Neurokinin Receptor (1)

PDGFR (1)

Phosphodiesterase (PDE) (1)

Potassium Channel (2)

Proton Pump (3)

Reactive Oxygen Species (2)

RET (1)

ROCK (1)

Toll-like Receptor (TLR) (1)

VEGFR (1)

By Research Areas:

Cancer (12)

Cardiovascular Disease (8)

Endocrinology (2)

Infection (13)

Inflammation/Immunology (20)

Metabolic Disease (17)

Neurological Disease (15)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-121826

Naronapride ATI-7505	5-HT Receptor	Metabolic Disease Inflammation/Immunology
Naronapride (ATI-7505) is a potent prokinetic 5-HT₄ receptor agonist. Naronapride can be used for gastrointestinal diseases research .

HY-17623C

(R)-Tegoprazan (R)-CJ-12420; (R)-RQ-00000004	Proton Pump	Metabolic Disease
(R)-Tegoprazan ((R)-CJ-12420; example 3), a benzimidazole derivative, is a potent kidney H ⁺/K ⁺-ATPase inhibitor with an IC₅₀ of 98 nM of canine kidney Na ⁺/K ⁺-ATPase. (R)-Tegoprazan has the potential for gastrointestinal diseases research .

HY-145578

Linaprazan glurate X842	Others	Inflammation/Immunology
Linaprazan glurate inhibits exogenously or endogenously stimulated gastric acid secretion. Linaprazan glurate exhibits several advantageous properties, such as fast onset, high in vivo potency and/or long duration of action. Linaprazan glurate is useful in the research of gastrointestinal inflammatory diseases and peptic ulcer diseases (extracted from patent WO2010063876A1) .

HY-142059

PDE5-IN-4	Phosphodiesterase (PDE)	Cardiovascular Disease Metabolic Disease
PDE5-IN-4 is a phosphodiesterase 5 inhibitor. PDE5-IN-4 can be used for the research of acute myocardial infarction and damage caused by reperfusion, gastrointestinal diseases, damage caused by diabetes, and liver failure .

HY-116016

Etilevodopa L-DOPA ethyl ester; Levodopa ethyl ester	Dopamine Receptor Drug Metabolite	Neurological Disease
Etilevodopa (L-Dopa ethyl ester), an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine .

HY-B0954A

Oxyphencyclimine	mAChR	Endocrinology
Oxyphencyclimine is an orally active muscarinic receptor (mAChR) antagonist. Oxyphencyclimine is effective in reducing ulceration index and increasing pepsin activity in rat gastric ulcer model. Oxyphencyclimine can be used in studies of peptic ulcer disease and gastrointestinal spasm .

HY-40294

Indazole	Monoamine Oxidase GSK-3 LRRK2	Cardiovascular Disease Neurological Disease Cancer
Indazole, also called isoindazole, a heterocyclic aromatic organic compound. Its derivatives display a broad variety of biological activities including anti-inflammatory, antibacterial, anti-HIV, antiarrhythmic, antifungal and antitumour properties. Indazole and its derivatives can be used for research of cancer, neurological disorders, cardiovascular diseases, gastrointestinal diseases .

HY-147564

RET-IN-18	RET	Neurological Disease Cancer
RET-IN-18 is a pyridone compound. is a potent inhibitor of RET. RET-IN-18 is a potent inhibitor of RET. RET-IN-18 has the potential for the research of diseases related to irritable bowel syndrome (IBS) and other gastrointestinal disorders, as well as cancers, and neurodegenerative diseases (extracted from patent WO2022017524A1, compound 1) .

HY-119127

TP-680	Cholecystokinin Receptor	Metabolic Disease
TP-680 is a cholecystokinin receptor antagonist. TP-680 binds 1510 times more strongly to rat pancreatic CCK_A receptors (IC₅₀=1.2 nM) than to rat brain CCK_B receptors (IC₅₀=1812.5 nM). TP-680 can be used in the study of gastrointestinal diseases .

HY-125996

NR1H4 activator 1	FXR	Inflammation/Immunology
NR1H4 activator 1 is a potent and selective Famesoid X Receptor (FXR) agonist, extracted from patent WO2018152171A1, example 4. NR1H4 activator 1 shows strong FXR agonistic potency with a EC₅₀ value of 1 nM in a Human FXR (NR1H4) Assay. NR1H4 activator 1 has the potential for treatment of gastrointestinal disease .

HY-116016A

Etilevodopa hydrochloride L-DOPA ethyl ester hydrochloride; Levodopa ethyl ester hydrochloride	Dopamine Receptor Drug Metabolite	Neurological Disease
Etilevodopa (L-Dopa ethyl ester) hydrochloride, an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa hydrochloride is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine .

HY-N8646

Isodonal	Others	Cancer
Isodonal is a N-pentane diterpene compound with potential cytotoxic, antitumor, inhibitory oxidative phosphorylation and antiingestion activities. Isodonal can be isolated from the leaves of *Isodon wikstroemioides and is used in the study of gastrointestinal* diseases, anti-tumor and anti-inflammatory .**

HY-B0189

Mosapride TAK-370; AS-4370	5-HT Receptor Cytochrome P450 Potassium Channel	Neurological Disease Cancer
Mosapride citrate is an orally active gastroenterokinetic compound. Mosapride citrate is a 5HT4agonist. Mosapride citrate is a CYP inducer. Mosapride citrate has a concentration-dependent inhibitory effect on Kv4.3, and its IC₅₀ value is 15.2 μM. Mosapride citrate can be used in the study of gastrointestinal diseases .

HY-B0189A

Mosapride citrate 4 Publications Verification TAK-370 citrate; AS-4370 citrate	5-HT Receptor Potassium Channel Cytochrome P450	Neurological Disease Cancer
Mosapride citrate is an orally active gastroenterokinetic compound. Mosapride citrate is a 5HT4 agonist. Mosapride citrate is a CYP inducer. Mosapride citrate has a concentration-dependent inhibitory effect on Kv4.3, and its IC₅₀ value is 15.2 μM. Mosapride citrate can be used in the study of gastrointestinal diseases .

HY-13771A

Ursodeoxycholic acid sodium Maximum Cited Publications 12 Publications Verification Ursodeoxycholate sodium; Ursodiol sodium; UCDA sodium	G protein-coupled Bile Acid Receptor 1 FXR Endogenous Metabolite	Metabolic Disease Inflammation/Immunology Cancer
Ursodeoxycholic acid (Ursodeoxycholate) sodium is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid sodium acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid sodium can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active .

HY-13771

Ursodeoxycholic acid Maximum Cited Publications 12 Publications Verification Ursodeoxycholate; Ursodiol; UDCA	G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite	Infection Metabolic Disease Cancer
Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .

HY-139557

Zastaprazan JP-1366	Proton Pump	Inflammation/Immunology
Zastaprazan (JP-1366) is a proton pump inhibitor (WO2018008929). Zastaprazan can be used for the research of gastrointestinal inflammatory diseases or gastric acid-related diseases .

HY-148795

Ritivixibat	Apical Sodium-Dependent Bile Acid Transporter	Cardiovascular Disease Metabolic Disease
Ritivixibat is an inhibitor of ileal bile acid transporter (IBAT), as well as a bile acid modulator. Ritivixibat can be used for research of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases .

HY-101646

Saviprazole HOE-731	Proton Pump	Cardiovascular Disease
Saviprazole is a Proton Pump inhibitor. Saviprazole can be used in research related to gastrointestinal diseases, such as gastric ulcers and acid reflux .

HY-U00382

Substance P Receptor Antagonist 1	Neurokinin Receptor	Neurological Disease Inflammation/Immunology
Substance P Receptor Antagonist 1 has the potential function in central nervous system disorders, respiratory, inflammatory diseases and gastrointestinal disorders.

HY-N4173

8-Oxoepiberberine	Drug Metabolite	Metabolic Disease
8-Oxoepiberberine is an alkaloid metabolite in the plasma after oral administration of Zuojin formula, a traditional chinese medicine used to treat gastrointestinal disease .

HY-B0691A

Ecabet sodium TA-2711	Reactive Oxygen Species Bacterial Apoptosis	Infection
Ecabet sodium (TA-2711) is currently applied to some gastrointestinal disease by inhibiting the ROS production and improving Helicobacter pylori eradication . Ecabet sodium reduces apoptosis .

HY-B0691

Ecabet	Reactive Oxygen Species Bacterial	Infection
Ecabet sodium (TA-2711) is currently applied to some clinical gastrointestinal disease by inhibiting the ROS production and improving Helicobacter pylori eradication . Ecabet sodium reduces apoptosis

HY-B0035S

Sulfamethazine-d4 Sulfadimidine-d₄; Sulfadimerazine-d₄	Bacterial	Infection
Sulfamethazine-d₄ is a deuterium labeled Sulfamethazine (Sulfadimidine). Sulfamethazine is an antimicrobial that is widely used to treat and prevent various animal diseases (such as gastrointestinal and respiratory tract infections)[1][2].

HY-16102

Bismuth subcitrate potassium	Bacterial Antibiotic	Infection
Bismuth subcitrate potassium is an antibiotic against 12 C. pyloridis strains with MIC₅₀ of 8 ug/ml . Bismuth subcitrate potassium is used to treat diseases of the upper gastrointestinal tract infected with Helicobacter pylori .

HY-136338

Cimetidine sulfoxide Cimetidine sulphoxide	Histamine Receptor	Inflammation/Immunology
Cimetidine sulfoxide (Cimetidine sulphoxide) is a sulfoxide metabolite of Cimetidine. Cimetidine is a histamine H₂-receptor antagonist. Cimetidine has the potential for peptic ulcer disease and upper gastrointestinal haemorrhage treatment .

HY-B0035

Sulfamethazine 1 Publications Verification Sulfadimidine; Sulfadimerazine	Bacterial Antibiotic	Infection
Sulfamethazine (Sulfadimidine) is an antimicrobial that is widely used to treat and prevent various animal diseases (such as gastrointestinal and respiratory tract infections). In China and the European Commission, the maximum residue level for Sulfamethazine in animal product is set at 100 μg/kg .

HY-B0035A

Sulfamethazine sodium 1 Publications Verification Sulfadimidine sodium; Sulfadimerazine sodium	Bacterial Antibiotic	Infection
Sulfamethazine sodium (Sulfadimidine sodium) is an antimicrobial that is widely used to treat and prevent various animal diseases (such as gastrointestinal and respiratory tract infections). In China and the European Commission, the maximum residue level for Sulfamethazine sodium in animal product is set at 100 µg/kg .

HY-156550

ROCK-IN-8	ROCK	Inflammation/Immunology
ROCK-IN-8 (Example 4) is a ROCK inhibitor, with an IC₅₀ value less than 100 nM. ROCK-IN-8 has anti-inflammatory activity. ROCK-IN-8 can be used for research of respiratory and gastro-intestinal diseases .

HY-B1806A

Tridihexethyl chloride Pathilon chloride	mAChR	Neurological Disease Inflammation/Immunology
Tridihexethyl (Pathilon) chloride is an orally active anticholinergic agent and mAChR antagonist, shows activities of antimuscarinic and anticholinergic. Tridihexethyl chloride shows pronounced antispasmodic and antisecretory effects on the gastrointestinal tract. Tridihexethyl chloride can be used in studies of peptic ulcer disease and acquired nystagmus .

HY-147243

Ansornitinib ANG-3070	VEGFR PDGFR	Cardiovascular Disease Inflammation/Immunology
Ansornitinib is an orally active dual kinase inhibitor that inhibits platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR2). Ansornitinib can be used as an antifibrotic agent in lung, liver, kidney, and gastrointestinal fibrotic diseases .

HY-122515

Fulvic Acid	Others	Metabolic Disease Inflammation/Immunology
Fulvic Acid is a natural product, which comes from humic substances produced by microorganisms in soil. Fulvic Acid can modulate the immune system, influence the oxidative state of cells, and improve gastrointestinal function. Fulvic Acid has the potential for researching chronic inflammatory diseases, including diabetes .

HY-147203

5-HT2B antagonist-1	5-HT Receptor	Cardiovascular Disease Metabolic Disease Endocrinology Cancer
5-HT2B antagonist-1 is an orally active 5-HT2B receptor antagonist with an IC₅₀ value of 33.4 nM. 5-HT2B antagonist-1 can be used in studies of diseases characterized by 5-HT2B receptor signaling, such as hepatocellular carcinoma, cardiovascular disease or gastrointestinal disease .

HY-B0732

Itopride hydrochloride HSR803	Cholinesterase (ChE) Dopamine Receptor Bacterial	Neurological Disease
Itopride (HSR803) hydrochloride is a potent dopamine-2 antagonist and an acetylcholine esterase (AChE) inhibitor. Itopride hydrochloride enhances gastric motility through both antidopaminergic and anti-acetylcholinesterasic actions, can be used as a gastrointestinal prokinetic agent. Itopride can be used for researching gastro-esophageal reflux disease (GERD) .

HY-B0035R

Sulfamethazine (Standard)	Bacterial Antibiotic	Infection
Sulfamethazine (Standard) is the analytical standard of Sulfamethazine. This product is intended for research and analytical applications. Sulfamethazine (Sulfadimidine) is an antimicrobial that is widely used to treat and prevent various animal diseases (such as gastrointestinal and respiratory tract infections). In China and the European Commission, the maximum residue level for Sulfamethazine in animal product is set at 100 μg/kg .

HY-136338R

Cimetidine sulfoxide (Standard)	Histamine Receptor	Inflammation/Immunology
Cimetidine sulfoxide (Standard) is the analytical standard of Cimetidine sulfoxide. This product is intended for research and analytical applications. Cimetidine sulfoxide (Cimetidine sulphoxide) is a sulfoxide metabolite of Cimetidine. Cimetidine is a histamine H2-receptor antagonist. Cimetidine has the potential for peptic ulcer disease and upper gastrointestinal haemorrhage treatment .

HY-B0732A

Itopride HSR803 free base	Cholinesterase (ChE) Dopamine Receptor Bacterial	Others
Itopride (HSR803 free base) is a potent and orally active dopamine-2 antagonist and an acetylcholine esterase (AChE) inhibitor. Itopride enhances gastric motility through both antidopaminergic and anti-acetylcholinesterasic actions, can be used as a gastrointestinal prokinetic agent. Itopride can be used for researching gastro-esophageal reflux disease (GERD) .

HY-10457A

Velusetrag hydrochloride TD-5108 hydrochloride	5-HT Receptor	Neurological Disease Metabolic Disease
Velusetrag (TD-5108) hydrochloride is an orally active, potent and selective agonist of serotonin 5-HT₄ receptor (5-HT₄R), with a pK_i of 7.7. Velusetrag hydrochloride exhibits no affinity (K_i>10 μM) for 5-HT_2A and 5-HT_2B receptors. Velusetrag hydrochloride can be used for the research of gastrointestinal diseases and Parkinson's disease .

HY-10457

Velusetrag TD-5108	5-HT Receptor	Neurological Disease Metabolic Disease
Velusetrag (TD-5108) is an orally active, potent and selective agonist of serotonin 5-HT₄ receptor (5-HT4R), with a pK_i of 7.7. Velusetrag exhibits no affinity (K_i>10 μM) for 5-HT_2A and 5-HT_2B receptors. Velusetrag can be used for the research of gastrointestinal diseases and Parkinson's disease .

HY-B0644

Sucralfate Sucrose octasulfate-aluminum complex	Bacterial	Infection Inflammation/Immunology Cancer
Sucralfate (Sucrose octasulfate-aluminum complex) is a potent and orally active gastroprotectant with no systemic effects. Sucralfate inhibits peptic activity and binds to negatively charged subepithelial proteins exposed during mucosal injury, forming a viscous layer that protects the vascular bed and proliferative zone. Sucralfate is used for prevention and research of several gastrointestinal diseases in vivo .

HY-117259

Valiltramiprosate ALZ-801	Amyloid-β	Neurological Disease
ALZ-801 is a potent and orally available small-molecule β-amyloid (Aβ) anti-oligomer and aggregation inhibitor, valine-conjugated proagent of Tramiprosate with substantially improved PK properties and gastrointestinal tolerability compared with the parent compound . ALZ-801 is an advanced and markedly improved candidate for the treatment of alzheimer’s disease .

HY-163415

MAO-IN-5	Monoamine Oxidase	Neurological Disease
MAO-IN-5 (Compound ZINC000016952895) is a monoamine oxidase (MAO) inhibitor. According to the prediction of Swiss ADME, MAO-IN-5 can inhibit the CYP enzyme family, has blood-brain barrier (BBB) permeability, and has a high gastrointestinal absorption rate. MAO-IN-5 can be used in the study of neurological diseases .

HY-122515R

Fulvic Acid (Standard)	Others	Metabolic Disease Inflammation/Immunology
Fulvic Acid (Standard) is the analytical standard of Fulvic Acid. This product is intended for research and analytical applications. Fulvic Acid is a natural product, which comes from humic substances produced by microorganisms in soil. Fulvic Acid can modulate the immune system, influence the oxidative state of cells, and improve gastrointestinal function. Fulvic Acid has the potential for researching chronic inflammatory diseases, including diabetes .

HY-P2797

Chitinase, Serratia marcescens AMCase, Serratia marcescens	Bacterial	Metabolic Disease Inflammation/Immunology
Chitinase, Serratia marcescens (EC 3.2.1.14) has partial lysozyme activity and is widely found in bacteria, fungi, animals and some plants. Chitinase belongs to the glycosyl hydrolase family. Chitinase catalyzes chito-oligosaccharide hydrolysis. Chitinases also can serve as prognostic biomarkers of disease progression. Chitinase can be used in the research of pathogenesis of various human fibrotic and inflammatory disorders, particularly those of the lung (idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, sarcoidosis, and asthma) and the gastrointestinal tract (inflammatory bowel diseases (IBDs) and colon cancer) .

HY-165495

Pafenolol	Adrenergic Receptor	Cardiovascular Disease
Pafenolol is a selectively oral-active β1 adrenergic receptor (β1-adrenergic receptor) antagonist that effectively lowers blood pressure. Pharmacokinetic studies in rats indicate that the absorption of Pafenolol is influenced by gastrointestinal contents, with food intake reducing the bioavailability of Pafenolol in rats. Pafenolol can be used in research related to cardiovascular diseases and asthma .

HY-B0732R

Itopride hydrochloride (Standard)	Cholinesterase (ChE) Dopamine Receptor Bacterial	Neurological Disease
Itopride (hydrochloride) (Standard) is the analytical standard of Itopride (hydrochloride). This product is intended for research and analytical applications. Itopride (HSR803) hydrochloride is a potent dopamine-2 antagonist and an acetylcholine esterase (AChE) inhibitor. Itopride hydrochloride enhances gastric motility through both antidopaminergic and anti-acetylcholinesterasic actions, can be used as a gastrointestinal prokinetic agent. Itopride can be used for researching gastro-esophageal reflux disease (GERD) .

HY-111313

JNJ-26070109	Cholecystokinin Receptor	Metabolic Disease
JNJ-26070109 is a high-affinity, competitive, orally bioactive, and selective cholecystokinin 2 (CCK2) receptor antagonist with good pharmacokinetic properties, with pK_is of 8.49, 7.99, and 7.70 for human, rat, and dog CCK2 receptors, respectively. The dual function of CCK2 receptors in regulating gastric acid secretion and growth of the gastrointestinal mucosa make this an attractive and novel target for the research of gastroesophageal reflux disease .

HY-B0644R

Sucralfate (Standard)	Bacterial	Infection Inflammation/Immunology Cancer
Sucralfate (Standard) is the analytical standard of Sucralfate. This product is intended for research and analytical applications. Sucralfate (Sucrose octasulfate-aluminum complex) is a potent and orally active gastroprotectant with no systemic effects. Sucralfate inhibits peptic activity and binds to negatively charged subepithelial proteins exposed during mucosal injury, forming a viscous layer that protects the vascular bed and proliferative zone. Sucralfate is used for prevention and research of several gastrointestinal diseases in vivo .

HY-124626

(R)-(+)-Mequitazine	Histamine Receptor	Inflammation/Immunology
(R)-(+)-Mequitazine is a histamine H1 receptor antagonist that mainly undergoes bio-transformation via human liver microsomes, resulting in hydroxylated and S-oxidized metabolites. (R)-(+)-Mequitazine competitively binds to the H1 receptors in gastrointestinal, vascular, and respiratory effect cells, thus blocking the endogenous activity of histamine. (R)-(+)-Mequitazine has an inhibitory effect on CYP3A-catalyzed midazolam 1’-hydroxylase. (R)-(+)-Mequitazine can be used in the study of various allergic diseases .

HY-13771S1

Ursodeoxycholic acid-13C Ursodeoxycholate-¹³C; Ursodiol-¹³C; UDCA-¹³C	Isotope-Labeled Compounds G protein-coupled Bile Acid Receptor 1 FXR Endogenous Metabolite	Cancer
Ursodeoxycholic acid- ¹³C is the ¹³C labeled Ursodeoxycholic acid. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active[1][2].

Cat. No.	Product Name

HY-L087

Anti-Obesity Compound Library

2,411 compounds

Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries.

MCE Anti-Obesity Compound Library owns a unique collection of 2,411 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.

Cat. No.	Product Name	Type

HY-D1056C1

Lipopolysaccharides, from S. enterica serotype enteritidis

LPS, from Salmonella enterica (Serotype enteritidis)

Carbohydrates

Lipopolysaccharides, from S. enterica serotype enteritidis is a lipopolysaccharide endotoxin that causes gastrointestinal disease in humans and can be transmitted through contaminated eggs or foods based on eggs and poultry meat products. S. enterica serotype enteritidis is capable of producing high molecular weight LPS-O antigen chains, Lipopolysaccharides, from S. enterica serotype typhimurium (HY-D1056C3) did not. S. enterica serotype enteritidis is similar to other pathogenic Salmonella. Lipopolysaccharides, from S. enterica serotype enteritidis' O antigen is associated with phage attachment in the early stages of phage infection S. Enteritidis .

HY-131384

8,11,14-Eicosatriynoic acid

8,11,14-Icosatriynoic acid

Biochemical Assay Reagents

8,11,14-Eicosatriynoic Acid, as an inhibitor of prostaglandin, leukotriene biosynthesis, and arachidonic acid-induced platelet aggregation, blocks human 12-lipoxygenase (12-LO), cyclooxygenase (COX)and 5-lipoxygenase (5-LO) with IC50 values of 0.46 μM, 14 μMand 25 μM, respectively. In addition, 8,11,14-Eicosatriynoic Acid inhibits the action of slow-reacting substances of allergic reactions, with IC50 value of 10 μM. Lipoxygenase is widely found in fungi, plants and animals. 12-LO involves in many important disease states and may play a role in oxidative glutamate toxicity. COX enzymes play complex roles in human physiology and pathology involving the neuronal, immune, renal, cardiovascular, gastrointestinal and reproductive systems. COX enzymes are blocked by aspirin and a variety of other NSAIDs, which makes them clinically important. 5-LO involves in cancer pathology. It is expressed by a variety of cancer cells, including colon, lung, breast, and prostate cancers, and promotes cancer cell growth and neovascularization . 8,11,14-Eicosatriynoic acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-13771A

Ursodeoxycholic acid sodium Maximum Cited Publications 12 Publications Verification Ursodeoxycholate sodium; Ursodiol sodium; UCDA sodium	Structural Classification Microorganisms Classification of Application Fields Source classification Metabolic Disease Inflammation/Immunology Disease Research Fields Steroids	G protein-coupled Bile Acid Receptor 1 FXR Endogenous Metabolite
Ursodeoxycholic acid (Ursodeoxycholate) sodium is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid sodium acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid sodium can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active .

HY-13771

Ursodeoxycholic acid Maximum Cited Publications 12 Publications Verification Ursodeoxycholate; Ursodiol; UDCA	Structural Classification Human Gut Microbiota Metabolites Microorganisms Other disease Classification of Application Fields Source classification Disease markers Endogenous metabolite Disease Research Fields Steroids Cancer	G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite
Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .

HY-N4173

8-Oxoepiberberine	Structural Classification other families Stilbenes Classification of Application Fields Source classification Metabolic Disease Plants Disease Research Fields	Drug Metabolite
8-Oxoepiberberine is an alkaloid metabolite in the plasma after oral administration of Zuojin formula, a traditional chinese medicine used to treat gastrointestinal disease .

HY-N8646

Isodonal	Structural Classification Terpenoids Labiatae Source classification Cirsium palustre (L.) Scop. Diterpenoids Plants	Others
Isodonal is a N-pentane diterpene compound with potential cytotoxic, antitumor, inhibitory oxidative phosphorylation and antiingestion activities. Isodonal can be isolated from the leaves of *Isodon wikstroemioides and is used in the study of gastrointestinal* diseases, anti-tumor and anti-inflammatory .**

HY-122515

Fulvic Acid	Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Phenols Polyphenols Disease Research Fields Inflammation/Immunology	Others
Fulvic Acid is a natural product, which comes from humic substances produced by microorganisms in soil. Fulvic Acid can modulate the immune system, influence the oxidative state of cells, and improve gastrointestinal function. Fulvic Acid has the potential for researching chronic inflammatory diseases, including diabetes .

HY-122515R

Fulvic Acid (Standard)	Structural Classification Microorganisms Ketones, Aldehydes, Acids Source classification Phenols Polyphenols	Others
Fulvic Acid (Standard) is the analytical standard of Fulvic Acid. This product is intended for research and analytical applications. Fulvic Acid is a natural product, which comes from humic substances produced by microorganisms in soil. Fulvic Acid can modulate the immune system, influence the oxidative state of cells, and improve gastrointestinal function. Fulvic Acid has the potential for researching chronic inflammatory diseases, including diabetes .

Cat. No.	Product Name	Chemical Structure

HY-B0035S

Sulfamethazine-d4
Sulfamethazine-d₄ is a deuterium labeled Sulfamethazine (Sulfadimidine). Sulfamethazine is an antimicrobial that is widely used to treat and prevent various animal diseases (such as gastrointestinal and respiratory tract infections)[1][2].

HY-113478S

Ursodeoxycholic acid-2,2,4,4-d4

Ursodeoxycholic acid-2,2,4,4-d₄ is the deuterium labeled Ursodeoxycholic acid (HY-13771). Ursodeoxycholic acid is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection[1][2][3][4][5].

HY-13771S1

Ursodeoxycholic acid-13C

Ursodeoxycholic acid- ¹³C is the ¹³C labeled Ursodeoxycholic acid. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active[1][2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

gastrointestinal diseases

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products